Recap: Alexion Pharmaceuticals Q2 Earnings

Shares of Alexion Pharmaceuticals ALXN rose 1.3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 17.80% year over year to $3.11, which beat the estimate of $2.59.

Revenue of $1,444,600,000 rose by 20.08% year over year, which beat the estimate of $1,280,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $10.65 and $10.95.

The upcoming fiscal year's revenue expected to be between $5,550,000,000 and $5,600,000,000.

How To Listen To The Conference Call

Date: Jul 30, 2020

Time: 08:00 AM

ET Webcast URL: https://ir.alexion.com/events-and-presentations

Recent Stock Performance

Company's 52-week high was at $125.52

Company's 52-week low was at $72.67

Price action over last quarter: Up 9.37%

Company Overview

Alexion Pharmaceuticals Inc specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.